Introduction: Tenofovir, an effective drug for treating AIDS and hepatitis B, is hot in China through illegal channels. So whether tenofovir is listed in China is very important to our patients. So, is tenofovir available in China? Tenofovir (tenofovir dipivoxil fumarate, TDF) is a new anti-HBV drug, two phase III registration clinical studies obtained four years of data show that tenofovir can effectively inhibit HBV replication and achieve histological and biochemical improvements, and tenofovir-related drug resistance variants have not been found. Tenofovir was approved by the U.S. FDA on August 11, 2008, for the treatment of chronic hepatitis B infection in adults. The recommended dose is the same as for HIV-infected patients, 300 mg/d, qd, with or without food; the dosing interval needs to be extended for those with renal insufficiency. So, in China, tenofovir is on the market? In January 2011, SFDA has approved the new drug clinical filing of tenofovir (TDF) for the treatment of chronic hepatitis B. This phase III clinical trial of TDF in China enrolled about 500 patients. During the initial 48-week treatment period, the efficacy and safety of tenofovir (300 mg/d) and adefovir (10 mg/d) will be compared in a double-blind, double-modeled, randomized controlled manner in Chinese patients with chronic hepatitis B. The subsequent 192 weeks will be an open monotherapy study in which all subjects will receive TDF 300 mg/d, with the aim of evaluating the long-term efficacy of TDF in Chinese patients with chronic The objective is to evaluate the long-term efficacy and safety of TDF in Chinese patients with chronic hepatitis B. All patients were enrolled in October 2011 and tenofovir disoproxil (TDF) is currently in a phase III clinical trial in China. The clinical approval of tenofovir disoproxil (TDF) upon completion of the registration clinical study in China will provide more treatment options for Chinese patients with chronic hepatitis B. Currently, TDF appears to be one of the most potent anti-HBV drugs with the lowest incidence of drug resistance. Especially in China, where the urgent problem is poor multidrug response or multidrug resistance, TDF-based antiviral therapy will be the most important option. The results of these two studies suggest that TDF can have good efficacy in patients with poor response or drug resistance, but more time and patient data are needed to evaluate.